Hydrogen spectroscopy in neurology;Espectroscopia de hidrógeno en neurología

Neurologia

Volumn 18, Issue 6, 2003, Pages 324-340

  Álvarez Linera Prado, Juan ^a   Escribano Vera, J ^a   Royo Orejas, A ^c   Benito Leon J ^b  

^a HOSPITAL RUBER INTERNACIONAL   (Spain)

^b HOSPITAL DE MÓSTOLES   (Spain)

^c Hospital Ruber Internacional ^*

Author keywords

Magnetic resonance imaging; Magnetic resonance spectroscopy

Indexed keywords

ALZHEIMER DISEASE; BRAIN PERFUSION; BRAIN TUMOR; CANCER RECURRENCE; DIAGNOSTIC VALUE; DIFFUSION; HUMAN; HYDROGEN SPECTROSCOPY; INFECTION; INFLAMMATION; MULTIPLE SCLEROSIS; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PELIZAEUS MERZBACHER DISEASE; RADIATION NECROSIS; REVIEW;

HUMANS; HYDROGEN; MAGNETIC RESONANCE IMAGING; NERVOUS SYSTEM DISEASES; NEUROLOGY;

EID: 0041564097     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Parnetti L, Lowenthal DT, Presciutti O, Pelliccioli GP, Palumbo R, Gobbi G, et al. 1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease. J Am Geriatr Soc 1996;44:133-8.
2. Jessen F, Block W, Traber F, Keller E, Flacke S, Lamerichs R, et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000;55:684-8.
3. Schuff N, Amend DL, Knowlton R, Norman D, Fein G, Weiner MW. Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain. Radiology 1998;207:91-102.
4. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993;187:433-7.
5. Valenzuela MJ, Sachdev PS, Wen W, Shnier R, Brodaty H, Gillies D. Dual voxel proton magnetic resonance spectroscopy in the healthy elderly: subcortical-frontal axonal N-acetylaspartate levels are correlated with fluid cognitive abilities independent of structural brain changes. Neuroimage 2000;12:747-56.
6. Moats RA, Shonk T. Evaluation of automated MR spectroscopy: application in Alzheimer disease. AJNR Am J Neuroradiol 1995;16:1779-82.
7. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995;195:65-72.
8. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994;32:110-5.
9. Parnetti L, Tarducci R, Presciutti O, Lowenthal DT, Pippi M, Palumbo B, et al. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev 1997;97:9-14.
10. Rose SE, de Zubicaray GI, Wang D, Galloway GJ, Chalk JB, Eagle SC, et al. A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imag 1999;17:291-9.
11. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997;203:829-36.
12. Kattapong VJ, Brooks WM, Wesley MH, Kodituwakku PW, Rosenberg GA. Proton magnetic resonance spectroscopy of vascular and Alzheimer-type dementia. Arch Neurol 1996;53:678-80.
13. MacKay S, Ezekiel F, Di Sclafani V, Meyerhoff DJ, Gerson J, Norman D, et al. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology 1996;198:537-45.
14. Doraiswamy PM, Charles HC, Krishnan KR. Prediction of cognitive decline in early Alzheimer's disease. Lancet 1998;352:1678.
15. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Tan J. In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am 1998;8:809-22.
16. Chen JG, Charles HC, Barboriak DP, Doraiswamy PM. Magnetic resonance spectroscopy in Alzheimer's disease: focus on Nacetylaspartate. Acta Neurol Scand Suppl 2000;176:20-6.
17. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000;355:1696-7.
18. Bluml S, Zuckerman E, Tan J, Ross BD. Proton-decoupled 31P magnetic resonance spectroscopy reveals osmotic and metabolic disturbances in human hepatic encephalopathy. J Neurochem 1998;71:1564-76.
19. Ross BD, Danielsen ER, Bluml S. Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy? Dig Dis 1996;14 (Suppl 1):30-9.
20. Videen JS, Michaelis T, Pinto P, Ross BD. Human cerebral osmolytes during chronic hyponatremia. A proton magnetic resonance spectroscopy study. J Clin Invest 1995;95:788-93.
21. Laubenberger J, Haussinger D, Bayer S, Gufler H, Hennig J, Langer M. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 1997;112:1610-6.
22. Ross BD, Jacobson S, Villamil F, Korula J, Kreis R, Ernst T, et al. Subclinical hepatic encephalopathy: proton MR spectroscopic abnormalities. Radiology 1994;193:457-63.
23. Thomās MA, Huda A, Guze B, Curran J, Bugbee M, Fairbanks L, et al. Cerebral 1H MR spectroscopy and neuropsychologic status of patients with hepatic encephalopathy. AJR Am J Roentgenol 1998;171:1123-30.
24. Savic I, Thomas AM, Ke Y, Curran J, Fried I, Engel J Jr. In vivo measurements of glutamine + glutamate (Glx) and N-acetyl aspartate (NAA) levels in human partial epilepsy. Acta Neurol Scand 2000;102:179-88.
25. Series W, Li LM, Caramanos Z, Arnold DL, Gotman J. Relation of interictal spike frequency to 1H-MRSI-measured NAA/Cr. Epilepsia 1999;40:1821-7.
26. Maton B, Gilliam F, Sawrie S, Faught E, Hugg J, Kuzniecky R. Correlation of scalp EEG and 1H-MRS metabolic abnormalities in temporal lobe epilepsy. Epilepsia 2001;42:417-22.
27. Cross JH, Gordon I, Connelly A, Jackson GD, Johnson CL, Neville BG, et al. Interictal 99mc(m) HMPAO SPECT and 1H MRS in children with temporal lobe epilepsy. Epilepsia 1997;38:338-45.
28. Maton BM, Kuzniecky RI. Proton MRS: N-acetyl aspartate, creatine, and choline. Adv Neurol 2000;83:253-9.
29. Duc CO, Trabesinger AH, Weber OM, Meier D, Walder M, Wieser HG, et al. Quantitative 1H MRS in the evaluation of mesial temporal lobe epilepsy in vivo. Magn Reson Imaging 1998;16:969-79.
30. Vainio P, Usenius JP, Vapalahti M, Partanen K, Kalviainen R, Rinne J, et al. Reduced N-acetylaspartate concentration in temporal lobe epilepsy by quantitative 1H MRS in vivo. Neuroreport 1994;5:1733-6.
31. Kikuchi S, Kubota F, Akata T, Shibata N, Hattori S, Oya N, et al. A study of the relationship between the seizure focus and 1HMRS in temporal lobe epilepsy and frontal lobe epilepsy. Psychiatry Clin Neurosci 2000;54:455-9.
32. Jackson GD, Connelly A. New NMR measurements in epilepsy. T2 relaxometry and magnetic resonance spectroscopy. Adv Neurol 1999;79:931-7.
33. Duncan JS. Imaging and epilepsy. Brain 1997;120:339-77.
34. Someya Y, Obata T, Suhara T, Ota Y, Ikehira H, Tanada S, et al. Seizure frequency and bilateral temporal abnormalities: a proton magnetic resonance spectroscopy of temporal lobe epilepsy. Seizure 2000;9:274-9.
35. Ende GR, Laxer KD, Knowlton RC, Matson GB, Schuff N, Fein G, et al. Temporal lobe epilepsy: bilateral hippocampal metabolite changes revealed at proton MR spectroscopic imaging. Radiology 1997;202:809-17.
36. Cendes F, Caramanos Z, Andermann F, Dubeau F, Arnold DL. Proton magnetic resonance spectroscopic imaging and magnetic resonance imaging volumetry in the lateralization of temporal lobe epilepsy: a series of 100 patients. Ann Neurol 1997;42:737-46.
37. Hugg JW, Kuzniecky RI, Gilliam FG, Morawetz RB, Fraught RE, Hetherington HP. Normalization of contralateral metabolic function following temporal lobectomy demonstrated by 1H magnetic resonance spectroscopic imaging. Ann Neurol 1996;40:236-9.
38. Hajek M, Dezortova M, Komarek V. 1H MR spectroscopy in patients with mesial temporal epilepsy. MAGMA 1998;7:95-114.
39. Achten E, Santens P, Boon P, De Coo D, Van De Kerckhove T, De Reuck J, et al. Value of single-voxel proton MR spectroscopy in temporal lobe epilepsy. AJNR Am J Neuroradiol 1997;18: 1131-9.
40. Kuzniecky R, Hugg J, Hetherington H, Martin R, Faught E, Morawetz R, et al. Predictive value of 1H MRSI for outcome in temporal lobectomy. Neurology 1999;53:694-8.
41. Vermathen P, Ende G, Laxer KD, Knowlton RC, Matson GB, Weiner MW. Hippocampal N-acetylaspartate in neocortical epilepsy and mesial temporal lobe epilepsy. Ann Neurol 1997;42:194-9.
42. Savic I, Lekvall A, Greitz D, Helms G. MR spectroscopy shows reduced frontal lobe concentrations of N-acetyl aspartate in patients with juvenile myoclonic epilepsy. Epilepsia 2000;41:290-6.
43. Stanley JA, Cendes F, Dubeau F, Andermann F, Arnold DL. Proton magnetic resonance spectroscopic imaging in patients with extratemporal epilepsy. Epilepsia 1998;39:267-73.
44. Mattson RH, Scheyer RD, Petroff OA, During MJ, Collins TL, Spencer D. Novel methods for studying new antiepileptic drug pharmacology. Adv Neurol 1998;76:105-12.
45. Petroff OA, Hyder F, Rothman DL, Mattson RH. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology 1999;52:473-8.
46. Petroff OA, Hyder F, Collins T, Mattson RH, Rothman DL: Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. Epilepsia 1999;40: 958-64.
47. Roser W, Hagberg G, Mader I, Brunnschweiler H, Radue EW, Seelig J, et al. Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal-appearing white matter. Magn Reson Med 1995;33:811-7.
48. Falini A, Calabrese G, Filippi M, Origgi D, Lipari S, Colombo B, et al. Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. AJNR Am J Neuroradiol 1998;19:223-9.
49. Hirsch JA, Lenkinski RE, Grossman RI. MR spectroscopy in the evaluation of enhancing lesions in the brain in multiple sclerosis. AJNR Am J Neuroradiol 1996;17:1829-36.
50. Landtblom AM, Sjoqvist L, Soderfeldt B, Nyland H, Thuomas KA. Proton MR spectroscopy and MR imaging in acute and chronic multiple sclerosis-ring like appearances in acute plaques. Acta Radiol 1996;37:278-87.
51. Castillo M, Kwock L, Scatliff JI, Mukherji SK. Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. Magn Reson Imaging Clin N Am 1998;6:1-20.
52. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998;121(Pt 1): 103-13.
53. Arnold DL, De Stefano N, Narayanan S, Matthews PM. Proton MR spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 2000;10:789-98.
54. Miller DH: Magnetic resonance imaging and spectroscopy in multiple sclerosis. Curr Opin Neurol 1995;8:210-5.
55. Matthews PM, Pioro E, Narayanan S, De Stefano N, Fu L, Francis G, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996;119:715-22.
56. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998;43:56-71.
57. Sarchielli P, Presciutti O, Tarducci R, Gobbi G, Alberti A, Pelliccioli GP, et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 1998;64:204-12.
58. Rubin Y, Cecil K, Wehrli S, McIntosh TK, Lenkinski RE, Smith DH. High-resolution 1H NMR spectroscopy following experimental brain trauma. J Neurotrauma 1997;14:441-9.
59. Cecil KM, Lenkinski RE, Meaney DF, McIntosh TK, Smith DH. High-field proton magnetic resonance spectroscopy of a swine model for axonal injury. J Neurochem 1998;70:2038-44.
60. Smith DH, Cecil KM, Meaney DF, Chen XH, McIntosh TK, Gennarelli TA, et al. Magnetic resonance spectroscopy of diffuse brain trauma in the pig. J Neurotrauma 1998;15:665-74.
61. Brooks WM, Friedman SD, Gasparovic C. Magnetic resonance spectroscopy in traumatic brain injury. J Head Trauma Rehabil 2001;16:149-64.
62. Condon B, Oluoch-Olunya D, Hadley D, Teasdale G, Wagstaff A. Early 1H magnetic resonance spectroscopy of acute head injury: four cases. J Neurotrauma 1998;15:563-71.
63. Ross BD, Ernst T, Kreis R, Haseler U, Bayer S, Danielsen E, Bluml S, et al. 1H MRS in acute traumatic brain injury. J Magn Reson Imaging 1998;8:829-40.
64. Holshouser BA, Ashwal S, Luh GY, Shu S, Kahlon S, Auld KL, et al. Proton MR spectroscopy after acute central nervous system injury: outcome prediction in neonates, infants, and children. Radiology 1997;202:487-96.
65. Friedman SD, Brooks WM, Jung RE, Chiulli SJ, Sloan JH, Montoya BT, et al. Quantitative proton MRS predicts outcome after traumatic brain injury. Neurology 1999;52:1384-91.
66. Brooks WM, Stidley CA, Petropoulos H, Jung RE, Weers DC, Friedman SD, et al. Metabolic and cognitive response to human traumatic brain injury: a quantitative proton magnetic resonance study. J Neurotrauma 2000;17:629-40.
67. Garnett MR, Blamire AM, Corkill RG, Cadoux-Hudson TA, Rajagopalan B, Styles P. Early proton magnetic resonance spectroscopy in normal-appearing brain correlates with outcome in patients following traumatic brain injury. Brain 2000;123: 2046-54.
68. Cecil KM, Hills EC, Sandel ME, Smith DH, McIntosh TK, Mannon U, et al. Proton magnetic resonance spectroscopy for detection of axonal injury in the splenium of the corpus callosum of brain-injured patients. J Neurosurg 1998;88:795-801.
69. Castillo M, Kwock L. Clinical applications of proton magnetic resonance spectroscopy in the evaluation of common intracranial tumors. Top Magn Reson Imaging 1999;10:104-13.
70. Kaibara T, Tyson RL, Sutherland GR. Human cerebral neoplasms studied using MR spectroscopy: a review. Biochem Cell Biol 1998;76:477-86.
71. Thomas MA, Ryner LN, Mehta MP, Turski PA, Sorenson JA. Localized 2D J-resolved 1H MR spectroscopy of human brain tumors in vivo. J Magn Reson Imaging 1996;6:453-9.
72. Shukla-Dave A, Gupta RK, Roy R, Husain N, Paul L, Venkatesh SK, et al. Prospective evaluation of in vivo proton MR spectroscopy in differentiation of similar appearing intracranial cystic lesions. Magn Reson Imaging 2001;19:103-10.
73. Negendank WG, Sauter R, Brown TR, Evelhoch JL, Falini A, Gotsis ED, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 1996;84:449-58.
74. Roser W, Hagberg G, Mader I, Dellas S, Seelig J, Radue EW, et al. Assignment of glial brain tumors in humans by in vivo 1H-magnetic resonance spectroscopy and multidimensional metabolic classification. MAGMA 1997;5:179-83.
75. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997;87: 516-24.
76. Ricci PE, Dungan DH. Imaging of low-and intermediate-grade gliomas. Semin Radiat Oncol 2001;11:103-12.
77. Bruhn H, Frahm J, Gyngell ML, Merboldt KD, Hanicke W, Sauter R, et al. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 1989;172:541-8.
78. Go KG, Kamman RL, Mooyaart EL, Heesters MA, Pruim J, Vaalburg W, et al. Localised proton spectroscopy and spectroscopic imaging in cerebral gliomas, with comparison to positron emission tomography. Neuroradiology 1995;37:198-206.
79. Herholz K, Heindel W, Luyten PR, denHollander JA, Pietrzyk U, Voges J, et al. In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 1992; 31:319-27.
80. Poptani H, Gupta RK, Roy R, Pandey R, Jain VK, Chhabra DK. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995;16:1593-603.
81. Shimizu H, Kumabe T, Tominaga T, Kayama T, Hara K, Ono Y, et al. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. AJNR Am J Neuroradiol 1996;17: 737-47.
82. Mader I, Roser W, Hagberg G, Schneider M, Sauter R, Seelig J, et al. Proton chemical shift imaging, metabolic maps, and single voxel spectroscopy of glial brain tumors. MAGMA 1996;4:139-50
83. Bovee WM, Rozijn TH, Van Der Sanden BP, Heerschap A. NMR perfusion and metabolic imaging and some examples on brain tumours. Cell Mol Biol (Noisy-le-grand) 1997;43:675-89.
84. Tzika AA, Vajapeyam S, Barnes PD: Multivoxel proton MR spectroscopy and hemodynamic MR imaging of childhood brain tumors: preliminary observations. AJNR Am J Neuroradiol 1997;18:203-18.
85. Furuya S, Naruse S, Ide M, Morishita H, Kizu O, Ueda S, et al. Evaluation of metabolic heterogeneity in brain tumors using 1H-chemical shift imaging method. NMR Biomed 1997;10: 25-30.
86. Lazareff JA, Gupta RK, Alger J. Variation of post-treatment HMRSI choline intensity in pediatric gliomas. J Neurooncol 1999;41:291-8.
87. Taylor JS, Ogg RJ, Langston JW. Proton MR spectroscopy of pediatric brain tumors. Neuroimaging Clin N Am 1998;8:753-79.
88. Alavi A, Alavi JB, Lenkinski RE. Complementary roles of PET and MR spectroscopy in the management of brain tumors. Radiology 1990;177:617-8.
89. Alger JR, Frank JA, Bizzi A, Fulham MJ, DeSouza BX, Duhaney MO, et al. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990;177:633-41.
90. Luyten PR, Marien AJ, Heindel W, van Gerwen PH, Herholz K, den Hollander JA, et al. Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology 1990;176:791-9.
91. Kizu O, Naruse S, Furuya S, Morishita H, Ide M, Maeda T, et al. Application of proton chemical shift imaging in monitoring of gamma knife radiosurgery on brain tumors. Magn Reson Imaging 1998;16:197-204.
92. Grand S, Esteve F, Remy C, Rubin C, Le Bas JF. Proton magnetic resonance spectroscopy: a metabolic approach of cerebral tumors and their follow-up after external radiation therapy. Rev Med Interne 1997;18:865-75.
93. Kwock L, Brown MA, Castillo M. Extraneous lipid contamination in single-volume proton MR spectroscopy: phantom and human studies. AJNR Am J Neuroradiol 1997;18:1349-57.
94. Ernst T, Chang L. Elimination of artifacts in short echo time H MR spectroscopy of the frontal lobe. Magn Reson Med 1996;36: 462-8.
95. Berry I, Moseley M, Germano IM, Ishige N, Nishimura MC, Bartkowski HM, et al. Combined magnetic resonance imaging and spectroscopy in experimental regional injury of the brain. Ischemia and impact trauma. Acta Radiol Suppl 1986;369:338-49.
96. Saunders DE, Howe FA, van den Boogaart A, Griffiths JR, Brown MM. Discrimination of metabolite from lipid and macromolecule resonances in cerebral infarction in humans using short echo proton spectroscopy. J Magn Reson Imaging 1997;7:1116-21.
97. Federico F, Simone IL, Conte C, Lucivero V, Giannini P, Liguori M, et al. Prognostic significance of metabolic changes detected by proton magnetic resonance spectroscopy in ischaemic stroke. J Neurol 1996;243:241-7.
98. Kamada K, Houkin K, Iwasaki Y, Abe H, Kashiwaba T. Metabolic and neurological patterns in chronic cerebral infarction: a singlevoxel 1H-MR spectroscopy study. Neuroradiology 1997;39:560-5.
99. van der Grond J, Ramos LM, Eikelboom BC, Mali WP. Cerebral metabolic differences between the severe and critical hypoperfused brain. Neurology 1996;47:399-404.
100. Kim GE, Lee JH, Cho YP, Kim ST. Metabolic changes in the ischemic penumbra after carotid endarterectomy in stroke patients by localized in vivo proton magnetic resonance spectroscopy (1H-MRS). Cardiovasc Surg 2001;9:345-55.
101. van der Grond J, van Everdingen KJ, Eikelboom BC, Kenez J, Mali WP. Assessment of borderzone ischemia with a combined MR imaging-MR angiography-MR spectroscopy protocol. J Magn Reson Imaging 1999;9:1-9.
102. Hetherington HP, Mason GF, Pan JW, Ponder SL, Vaughan JT, Twieg DB, et al. Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1T. Magn Reson Med 1994;32:565-71.
103. Tedeschi G, Bertolino A, Righini A, Campbell G, Raman R, Duyn JH, et al. Brain regional distribution pattern of metabolite signal intensities in young adults by proton magnetic resonance spectroscopic imaging. Neurology 1995;45:1384-91.
104. Frahm J, Hanefeld F. Localized proton magnetic resonance spectroscopy of cerebral metabolites. Neuropediatrics 1996;27:64-9.
105. Huppi PS, Fusch C, Boesch C, Burri R, Bossi E, Amato M, et al. Regional metabolic assessment of human brain during development by proton magnetic resonance spectroscopy in vivo and by high-performance liquid chromatography/gas chromatography in autopsy tissue. Pediatr Res 1995;37:145-50.
106. Kreis R, Ernst T, Ross BD. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med 1993;30:424-37.
107. van der Knaap MS, van der Grond J, van Rijen PC, Faber JA, Valk J, Willemse K. Age-dependent changes in localized proton and phosphorus MR spectroscopy of the brain. Radiology 1990;176:509-15.
108. Lim KO, Spielman DM. Estimating NAA in cortical gray matter with applications for measuring changes due to aging. Magn Reson Med 1997;37:372-7.
109. Austin SJ, Connelly A, Gadian DG, Benton JS, Brett EM. Localized 1H NMR spectroscopy in Canavan's disease: a report of two cases. Magn Reson Med 1991;19:439-45.
110. Barker PB, Bryan RN, Kumar AJ, Naidu S. Proton NMR spectroscopy of Canavan's disease. Neuropediatrics 1992;23:263-7.
111. Schulze A, Hess T, Wevers R, Mayatepek E, Bachert P, Marescau B, et al. Creatine deficiency syndrome caused by guanidinoacetate methyltransferase deficiency: diagnostic tools for a new inborn error of metabolism. J Pediatr 1997;131:626-31.
112. Clark JM, Marks MP, Adalsteinsson E, Spielman DM, Shuster D, Horoupian D, et al. MELAS: Clinical and pathologic correlations with MRI, xenon/CT, and MR spectroscopy. Neurology 1996;46:223-7.
113. Gadian DG, Leonard JV. The role of magnetic resonance spectroscopy in the investigation of lactic acidosis and inborn errors of energy metabolism. J Inherit Metab Dis 1996;19:548-52.
114. Lam WW, Wang ZJ, Zhao H, Berry GT, Kaplan P, Gibson J, et al. 1H MR spectroscopy of the basal ganglia in childhood: a semi-quantitative analysis. Neuroradiology 1998;40:315-23.
115. Ross B, Kreis R, Ernst T. Clinical tools for the 90s: magnetic resonance spectroscopy and metabolite imaging. Eur J Radiol 1992;14:128-40.
116. Wang ZJ, Zimmerman RA. Proton MR spectroscopy of pediatric brain metabolic disorders. Neuroimaging Clin N Am 1998;8:781-807.
117. Felber SR, Sperl W, Chemelli A, Murr C, Wendel U. Maple syrup urine disease: metabolic decompensation monitored by proton magnetic resonance imaging and spectroscopy. Ann Neurol 1993;33:396-401.
118. Moller HE, Weglage J, Wiedermann D, Vermathen P, Bick U, Ullrich K. Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo. Brain Res 1997;778:329-37.
119. Kreis R, Pietz J, Penzien J, Herschkowitz N, Boesch C. Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy. J Magn Reson B 1995;107:242-51.
120. Pietz J, Kreis R, Schmidt H, Meyding-Lamade UK, Rupp A, Boesch C. Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. Radiology 1996;201:413-20.
121. Brockmann K, Pouwels PJ, Christen HJ, Frahm J, Hanefeld F. Localized proton magnetic resonance spectroscopy of cerebral metabolic disturbances in children with neuronal ceroid lipofuscinosis. Neuropediatrics 1996;27:242-8.
122. Seitz D, Grodd W, Schwab A, Seeger U, Klose U, Nagele T. MR imaging and localized proton MR spectroscopy in late infantile neuronal ceroid lipofuscinosis. AJNR Am J Neuroradiol 1998;19:1373-7.
123. Zimmerman RA, Wang ZJ. The value of proton MR spectroscopy in pediatric metabolic brain disease. AJNR Am J Neuroradiol 1997;18:1872-9.
124. Detre JA, Wang ZY, Bogdan AR, Gusnard DA, Bay CA, Bingham PM, et al. Regional variation in brain lactate in Leigh syndrome by localized 1H magnetic resonance spectroscopy. Ann Neurol 1991;29:218-21.
125. Pouwels PJ, Kruse B, Korenke GC, Mao X, Hanefeld FA, Frahm J. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. Neuropediatrics 1998;29:254-64.
126. Rajanayagam V, Grad J, Krivit W, Loes DJ, Lockman L, Shapiro E, et al. Proton MR spectroscopy of childhood adrenoleukodystrophy. AJNR Am J Neuroradiol 1996;17:1013-24.
127. Korenke GC, Pouwels PJ, Frahm J, Hunneman DH, Stoeckler S, Krasemann E, et al. Arrested cerebral adrenoleukodystrophy: a clinical and proton magnetic resonance spectroscopy study in three patients. Pediatr Neurol 1996;15:103-7.
128. Paley M, Cozzone PJ, Alonso J, Vion-Dury J, Confort-Gouny S, Wilkinson ID, et al. A multicenter proton magnetic resonance spectroscopy study of neurological complications of AIDS. AIDS Res Hum Retroviruses 1996;12:213-22.
129. Vion-Dury J, Salvan AM, Confort-Gouny S, Cozzone PJ. Brain proton magnetic resonance spectroscopy. Indications for diagnosis and follow-up of HIV-related encephalopathy in the adult. Presse Med 1998;27:1398-405.
130. Alonso J, Rovira A, Capellades J, Ocaña I, Rio J, Wicklow K, et al. Espectroscopia de hidrógeno cerebral en personas infectadas con el virus de inmunodeficiencia humana. Med Clin (Barc) 1996;107:361-5.
131. Marcus CD, Taylor-Robinson SD, Sargentoni J, Ainsworth JG, Frize G, Easterbrook PJ, et al. 1H MR spectroscopy of the brain in HIV-1-seropositive subjects: evidence for diffuse metabolic abnormalities. Metab Brain Dis 1998;13:123-36.
132. Jarvik JG, Lenkinski RE, Saykin AJ, Jaans A, Frank I. Proton MR spectroscopy of HIV-infected patients: characterization of abnormalities with imaging and clinical correlation. Radiology 1993;186:739-44.
133. Cecil KM, Lenkinski RE. Proton MR spectroscopy in inflammatory and infectious brain disorders. Neuroimaging Clin N Am 1998;8:863-80.
134. Moller HE, Vermathen P, Lentschig MG, Schuierer G, Schwarz S, Wiedermann D, et al. Metabolic characterization of AIDS dementia complex by spectroscopic imaging. J Magn Reson Imaging 1999;9:10-8.
135. Simone IL, Federico F, Tortorella C, Andreula CF, Zimatore GB, Giannini P, et al. Localised 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV. J Neurol Neurosurg Psychiatry 1998;64:516-23.
136. Vion-Dury J, Nicoli F, Salvan AM, et al. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet 1995;345:60-1.
137. Pavlakis SG, Lu D, Frank Y, Wizma A, Eidelberg D, et al. Brain lactate and N-acetylaspartate in pediatric AIDS encephalopathy. AJNR Am J Neuroradiol 1998;19:383-5.
138. Poptani H, Gupta RK, Jain VK, Jain VK, Roy R, Pandey R. Cystic intracranial mass lesions: possible role of in vivo MR spectroscopy in its differential diagnosis. Magn Reson Imaging 1995;13:1019-29.
139. Dev R, Gupta RK, Poptani H, Roy R, Sharma S, Husain M. Role of in vivo proton magnetic resonance spectroscopy in the diagnosis and management of brain abscesses. Neurosurgery 1998;42:37-42.
140. Gupta RK, Roy R, Dev R, Husain M, Poptani H, Pandey R, et al. Finger printing of Mycobacterium tuberculosis in patients with intracranial tuberculomas by using in vivo, ex vivo, and in vitro magnetic resonance spectroscopy. Magn Reson Med 1996;36:829-33.
141. Menon DK, Sargentoni J, Peden CJ, Bell JD, Cox IJ, Coutts GA, et al. Proton MR spectroscopy in herpes simplex encephalitis: assessment of neuronal loss. J Comput Assist Tomogr 1990;14:449-52.
142. Demaerel P, Wilms G, Robberecht W, Johannik K, Van Hecke P, Carton H, et al. MRI of herpes simplex encephalitis. Neuroradiology 1992;34:490-3.
143. Venkatesh SK, Gupta RK, Pal L, Husain N, Husain M. Spectroscopic increase in choline signal is a nonspecific marker for differentiation of infective/inflammatory from neoplastic lesions of the brain. J Magn Reson Imaging 2001;14:8-15.
144. Takanashi J, Sugita K, Ishii M, Aoyagi M, Niimi H. Longitudinal MR imaging and proton MR spectroscopy in herpes simplex encephalitis. J Neurol Sci 1997;149:99-102.